Alcon (NYSE:ALC) Stock

Alcon

Alcon is one of the leading visioncare companies in the world. Following nine years as a Novartis subsidiary, it was spun off as a public company in April 2019. Alcon operates in two segments: visioncare and surgical. Visioncare comprises contact lenses, lenscare solutions, and a suite of ocular health products. With brands like Dailies, Total1, and Air Optix, Alcon controls about one fourth of the US contact lens market. Surgical comprises intraocular lenses, ophthalmic surgical equipment, and consumables used during surgeries. Its main products include Centurion, a phacoemulsification device used during cataract surgeries, and a portfolio of IOLs including PanOptix and Vivity. Alcon has one of the largest installed bases of eye surgical equipment in the world.

Alcon Inc

ALTERNUS CLEAN ENGY INC A by Alternus Clean Energy, Inc.

Alternus Clean Energy Inc

ALLIANCE INTL EDCATN LSNG by ALLIANCE INTL EDUCATION LEASING HLDGS LTD.

Alliance International Education Leasing Holdings Ltd

ALTECH CORP KANAGAWA by ALTECH CORP KANAGAWA

Altech Corp

ATLANTIC CNTRL ENTRPR LTD by Atlantic Central Enterprise Ltd.

Atlantic Central Enterprises Ltd

Alico Inc

ALCHIP TECHNOLOGS LTD TWD by ALCHIP TECHNOLOGIES LIMITED

Alchip Technologies Ltd

Alpha Copper Corp Ordinary Shares

Alchemix - United States Dollar

Alchemy Investments Acquisition Corp 1 - Class A Ordinary Shares

Alchemy Investments Acquisition Corp 1

Alchemy Investments Acquisition Corp 1 - Units

Alchemy Investments Acquisition Corp 1 - Warrants

<ul>
<li>Alcon welcomes its shareholders to its third in-person AGM</li>
<li>Alcon Board of Directors proposes to elect Deborah Di Sanzo as a new Board member</li>
<li>Proposed dividend of CHF 0.28 cash per share</li>
</ul>

News

Alcon Proposes CHF 0.28 Cash Dividend Ahead Of 2025 AGM And Nomination Of New Tech-Focused Board Member

Keybanc analyst Brett Fishbin maintains Alcon (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALC#NYSE">ALC</a>) with a Overweight and raises the price target from $108 to $112.

Price Target

Analyst Ratings

Keybanc Maintains Overweight on Alcon, Raises Price Target to $112

Mizuho analyst Anthony Petrone maintains Alcon (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALC#NYSE">ALC</a>) with a Outperform and raises the price target from $115 to $120.

Mizuho Maintains Outperform on Alcon, Raises Price Target to $120

Needham analyst David Saxon maintains Alcon (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALC#NYSE">ALC</a>) with a Buy and raises the price target from $107 to $110.

Needham Maintains Buy on Alcon, Raises Price Target to $110

WIIM

Alcon shares are trading higher. The company acquired majority interest in Aurion Biotech.

<ul>
<li>Leverages Alcon's global scale with Aurion's cell therapy expertise to accelerate U.S. Phase 3 development in fall of 2025</li>
<li>Aurion's lead asset received Breakthrough Therapy Designation and Regenerative Medicine Advanced Therapy Designation from the U.S. Food and Drug Administration (FDA)</li>
<li>Positions Alcon at the leading edge of biopharma applications in ophthalmology with the potential to advance the first-ever corneal cell therapy candidate</li>
</ul>

Alcon Acquires Majority Interest in Aurion Biotech; Financial Terms Not Disclosed

<ul>
<li>Clareon Vivity IOL provides an extended range of vision from distance to functional near with a monofocal visual disturbance profile1-3µ‖</li>
<li>Vivity, the world's leading EDOF, is now available on Alcon's Clareon material, providing presbyopia correction with exceptional† clarity and predictable refractive outcomes1,4-7</li>
<li>CE Marked countries will begin commercial rollout of Clareon Vivity and Clareon Vivity Toric from early Q2 2025; also available in AutonoMe automated pre-loaded delivery system in Q3 20258</li>
</ul>

Alcon Secures CE Mark For Clareon Vivity IOL, Bringing Next-Generation Presbyopia Correction To Europe

Shares of eye care company Alcon AG (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALC#NYSE">ALC</a>) are <a target="_blank" href="https://www.benzinga.com/movers" rel="noreferrer noopener">trading higher on Monday</a>.
The company has agreed to acquire LENSAR Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNSR#NASDAQ">LNSR</a>), a firm recognized for its laser solutions in cataract surgery.
Under the terms of the deal, Alcon will purchase LENSAR shares for&nbsp;$14.00&nbsp;per share in cash for an aggregate implied value of approximately&nbsp;$356 million. The deal also an additional non-tradeable contingent value right offering up to&nbsp;$2.75&nbsp;per share in cash, conditioned on the achievement of 614,000 cumulative procedures with LENSAR&#8217;s products between January 1, 2026, and December 31, 2027. The transaction represents a total consideration of up to approximately&nbsp;$430 million.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/03/44456336/james-hardie-acquires-building-products-maker-azek-for-875b-stock-plummets" rel="noreferrer noopener">James Hardie To Acquire AZEK In $8.75 Billion Deal, Expanding Its Grip On Outdoor Living Market</a>
The transaction is set to close by mid-to-late 2025, pending regulatory and shareholder approvals. Alcon held <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/b43957894/alcon-reports-full-year-2024-results-with-strong-top-line-and-earnings-growth-and-record-cash-gene" rel="noreferrer noopener">$1.7 billion in cash and equivalents </a>as of December 31, 2024.
&#8220;We are excited for the opportunity to bring LENSAR&#8217;s unique next-generation technologies and intellectual property into our innovative, market-leading equipment portfolio,&#8221; said Alcon CEO David Endicott.
&#8220;By leveraging our global footprint, we have the opportunity to deliver the benefits of advanced femtosecond laser technology to many more surgeons around the world and continue to improve efficiency in cataract surgery.&#8221;
The acquisition will expand Alcon&#8217;s femtosecond laser-assisted cataract surgery (FLACS) offerings by integrating LENSAR&#8217;s ALLY Robotic Cataract Laser System, Streamline software, and additional laser technologies.
The system aims to reduce reliance on blade incisions while improving surgical outcomes, particularly in managing astigmatism and other complex cataract conditions.
Currently, there are more than 5 million cataract procedures in the U.S. and approximately 32 million globally.
Price Action: ALC stock traded higher by 1.91% at $92.29 while LNSR is down 2.40% at $14.47 at last check Monday.
Read Next:<a target="_blank" href="https://www.benzinga.com/25/03/44456578/why-dna-test-provider-23andmes-stock-is-plunging-today" rel="noreferrer noopener"></a>
<ul>
<li><a href="https://www.benzinga.com/25/03/44456578/why-dna-test-provider-23andmes-stock-is-plunging-today" target="_blank" rel="noreferrer noopener">Why Is DNA Test Provider 23andMe Stock Tumbling Today?</a></li>
</ul>
Image via Shutterstock.

Equities

Movers

General

LNSR

Alcon Eyes Surgical Edge With LENSAR Buyout: Details

Alcon To Acquire LENSAR For $14/Share

Needham analyst David Saxon reiterates Alcon (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALC#NYSE">ALC</a>) with a Buy and maintains $107 price target.

Reiteration

Needham Reiterates Buy on Alcon, Maintains $107 Price Target

Baird analyst Jeff Johnson maintains Alcon (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALC#NYSE">ALC</a>) with a Outperform and raises the price target from $104 to $108.

Baird Maintains Outperform on Alcon, Raises Price Target to $108

Needham analyst David Saxon maintains Alcon (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALC#NYSE">ALC</a>) with a Buy and raises the price target from $106 to $107.

Needham Maintains Buy on Alcon, Raises Price Target to $107

Alcon shares are trading higher after the company reported better-than-expected Q4 financial results.

Needham analyst David Saxon reiterates Alcon (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALC#NYSE">ALC</a>) with a Buy and maintains $106 price target.

Needham Reiterates Buy on Alcon, Maintains $106 Price Target

Guidance

Alcon Sees FY25 EPS $3.15-$3.25 Vs $3.36 Est.; Revenue $10.2B-$10.4B Vs $10.461B Est.

Alcon (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALC#NYSE">ALC</a>) reported quarterly earnings of $0.72 per share which beat the analyst consensus estimate of $0.71 by 1.41 percent. This is a 2.86 percent increase over earnings of $0.70 per share from the same period last year. The company reported quarterly sales of $2.477 billion which beat the analyst consensus estimate of $2.466 billion by 0.45 percent. This is a 6.22 percent increase over sales of $2.332 billion the same period last year.

Earnings

Earnings Beats

Alcon Q4 2024 Adj. EPS $0.72 Beats $0.71 Estimate, Sales $2.477B Beat $2.466B Estimate

AHCO

ALLT

ARQT

AXGN

AXON

BASE

BGFV

BLZE

BTDR

BWIN

CART

CAVA

CBLL

CCCS

CECO

CGBD

CHRD

CIFR

CPNG

CPSS

DAWN

DNUT

DOCN

DRVN

ELAN

EXLS

FIHL

FLYW

FSLR

FULC

GPOR

HRMY

HSIC

HURN

HYLN

IART

ICCC

IGIC

IMOS

INGN

INTU

INVX

IPAR

ITRI

IVAC

JACK

JAZZ

KEYS

KNSA

LCID

LGIH

LIVN

LMND

LXFR

MASI

MATX

MFIC

MIDD

MMSI

MPLN

MRVI

NOVT

NXRT

Earnings Scheduled For February 25, 2025

Keybanc analyst Brett Fishbin maintains Alcon (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALC#NYSE">ALC</a>) with a Overweight and lowers the price target from $107 to $105.

Keybanc Maintains Overweight on Alcon, Lowers Price Target to $105

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>JP Morgan raised the price target for Bath &amp; Body Works, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBWI#NYSE">BBWI</a>) from $39 to $41. JP Morgan analyst Matthew Boss maintained a Neutral rating. Bath &amp; Body Works shares closed at $37.29 on Thursday. <a href="https://www.benzinga.com/quote/BBWI/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Morgan Stanley cut AvalonBay Communities, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AVB#NYSE">AVB</a>) price target from $236 to $223. Morgan Stanley analyst Adam Kramer downgraded the stock from Overweight to Equal-Weight. AvalonBay Communities shares closed at $213.80 on Thursday. <a href="https://www.benzinga.com/quote/AVB/analyst-ratings">See how other analysts view this stoc</a>k.</li>
<li>HC Wainwright &amp; Co. raised the price target for LSI Industries Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LYTS#NASDAQ">LYTS</a>) from $20 to $30. HC Wainwright &amp; Co. analyst Amit Dayal maintained a Buy rating. LSI Industries shares closed at $24.72 on Thursday. <a href="https://www.benzinga.com/quote/LYTS/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Needham cut the price target for Alcon Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALC#NYSE">ALC</a>) from $108 to $106. Needham analyst David Saxon maintained a Buy rating. Alcon shares closed at $89.11 on Thursday. <a href="https://www.benzinga.com/quote/ALC/analyst-ratings">See how other analysts view this stoc</a>k.</li>
<li>B of A Securities cut Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) price target from $256 to $253. B of A Securities analyst Wamsi Mohan maintained a Buy rating. Apple shares settled at $223.66 on Thursday. <a href="https://www.benzinga.com/quote/AAPL/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Jefferies raised Atlassian Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEAM#NASDAQ">TEAM</a>) price target from $300 to $325. Jefferies analyst Brent Thill maintained a Buy rating. Atlassian shares closed at $265.70 on Thursday. <a href="https://www.benzinga.com/quote/TEAM/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Piper Sandler increased The Travelers Companies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TRV#NYSE">TRV</a>) price target from $259 to $310. Piper Sandler analyst Paul Newsome upgraded the stock from Neutral to Overweight. Travelers shares closed at $241.51 on Thursday.  <a href="https://www.benzinga.com/quote/TRV/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Citigroup cut the price target for New Oriental Education &amp; Technology Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EDU#NYSE">EDU</a>) from $83 to $50. Citigroup analyst Michelle Fang downgraded the stock from Buy to Neutral. New Oriental Education shares settled at $46.75 on Wednesday. <a href="https://www.benzinga.com/quote/EDU/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Piper Sandler boosted Mastercard Incorporated (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MA#NYSE">MA</a>) price target from $575 to $591. Piper Sandler analyst Arvind Ramnani maintained an Overweight rating. Mastercard shares closed at $534.22 on Thursday. <a href="https://www.benzinga.com/quote/MA/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Baird increased Twilio Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TWLO#NYSE">TWLO</a>) price target from $115 to $160. Baird analyst William Power upgraded the stock from Neutral to Outperform. Twilio shares closed at $113.40 on Thursday. <a href="https://www.benzinga.com/quote/TWLO/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/01/43158901/jim-cramer-says-this-tech-stock-is-speculative-but-he-likes-it">Jim Cramer Says This Tech Stock Is Speculative But He Likes It</a></li>
</ul>

Pre-Market Outlook

Markets

Trading Ideas

AAPL

BBWI

New Oriental Education & Technology Group

LYTS

TEAM

TWLO

Apple To $253? Here Are 10 Top Analyst Forecasts For Friday

Needham analyst David Saxon maintains Alcon (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALC#NYSE">ALC</a>) with a Buy and lowers the price target from $108 to $106.

Needham Maintains Buy on Alcon, Lowers Price Target to $106

Press Releases

Alcon Reports Full-Year 2024 Results, with Strong Top-line and Earnings Growth and Record Cash Generation

Alcon Canada Strengthens its Commitment to Astigmatic Patients with TOTAL30 for Astigmatism Expanded Parameters

Alcon to Host 2025 Capital Markets Day

Alcon Agrees to Acquire LENSAR, Inc.

Alcon Announces CE Mark Approval and Commercialization of Clareon Vivity IOL in Europe, Expanding Visual Possibilities

LENSAR INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of LENSAR, Inc. - LNSR

Alcon Acquires Majority Interest in Aurion Biotech, Inc. to Advance Innovative Cell Therapy for Corneal Endothelial Disease

Alcon Expands Leadership in IOL Innovation with Clareon PanOptix Pro, Delivering Best-in-Class Light Utilization and Less Light Scatter

Comments

Alcon

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL